Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15131148 | 0.86 | SMN1; SMN2 (0.63) | HRH3SMN1; SMN2SIGMAR1POLBHTT | |
| SCHEMBL5618352 | 0.82 | SMN1; SMN2 (0.71) | HRH3SMN1; SMN2MEN1NPC1TP53 | |
| SCHEMBL19542004 | 0.82 | MAPT (0.62) | MAPTHRH3SMN1; SMN2NPC1TP53 | |
| SCHEMBL4547887 | 0.81 | HRH3 (0.65) | MAPTHRH3SMN1; SMN2HTT | |
| SCHEMBL14872333 | 0.80 | HRH3 (0.59) | HRH3SMN1; SMN2MEN1NPC1TP53 | |
| SCHEMBL12295393 | 0.80 | MAPT (0.62) | MAPTHRH3SMN1; SMN2MEN1NPC1 | |
| SCHEMBL13161945 | 0.80 | HRH3 (0.62) | HRH3SMN1; SMN2MEN1NPC1TP53 | |
| SCHEMBL19441606 | 0.80 | HRH3 (0.62) | MAPTHRH3SMN1; SMN2HTT | |
| SCHEMBL19441582 | 0.80 | HRH3 (0.62) | MAPTHRH3SMN1; SMN2HTT | |
| SCHEMBL21925208 | 0.79 | MAPT (0.58) | MAPTHRH3SMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | MAPT 1488/4885HRH3 307/4885SMN1; SMN2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.